Compugen Ltd. (CGEN)

4.32
0.09 2.10
NASDAQ : Health Technology
Prev Close 4.23
Open 4.23
Day Low/High 4.14 / 4.29
52 Wk Low/High 2.00 / 4.31
Volume 74.74K
Avg Volume 221.50K
Exchange NASDAQ
Shares Outstanding 61.96M
Market Cap 254.14M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Compugen Expands Intellectual Property Portfolio For COM701 With New U.S. Patent Covering Combination Use With Anti-PD-1 Antibody

Compugen Expands Intellectual Property Portfolio For COM701 With New U.S. Patent Covering Combination Use With Anti-PD-1 Antibody

Previously granted U.S. Patent protects combination of COM701 and COM902

Compugen Appoints Eran Perry To Its Board Of Directors

Compugen Appoints Eran Perry To Its Board Of Directors

HOLON, Israel, July 2, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the appointment of Mr.

Compugen Presents Update On COM701 Phase 1 Trial At The 2019 ASCO Annual Meeting

Compugen Presents Update On COM701 Phase 1 Trial At The 2019 ASCO Annual Meeting

HOLON, Israel, June 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class...

Compugen To Present At The Jefferies 2019 Healthcare Conference

Compugen To Present At The Jefferies 2019 Healthcare Conference

HOLON, Israel, May 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that Anat Cohen-Dayag, PhD, President and CEO, will present...

Compugen Reports First Quarter 2019 Results

Compugen Reports First Quarter 2019 Results

HOLON, Israel, May 20, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the first quarter ended March 31, 2019.

Compugen Doses First Patient In COM701/Opdivo® (Nivolumab) Combination Arm Of Phase 1 Study In Patients With Advanced Solid Tumors

Compugen Doses First Patient In COM701/Opdivo® (Nivolumab) Combination Arm Of Phase 1 Study In Patients With Advanced Solid Tumors

Study based on well-tolerated doses with no reported DLTs of COM701 identified in monotherapy dose escalation arm of Phase 1 study

Compugen First Quarter 2019 Conference Call Scheduled For Monday, May 20, 2019 At 8:30 AM ET

Compugen First Quarter 2019 Conference Call Scheduled For Monday, May 20, 2019 At 8:30 AM ET

HOLON, Israel, May 6, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its first quarter 2019...

Compugen Presents Update On COM701 Phase 1 Trial At The 2019 AACR Annual Meeting

Compugen Presents Update On COM701 Phase 1 Trial At The 2019 AACR Annual Meeting

HOLON, Israel, April 3, 2019 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a...

Chinese Regulatory Authority [NMPA] Approves IND Application Of Oramed's Oral Insulin Capsules

Chinese Regulatory Authority [NMPA] Approves IND Application Of Oramed's Oral Insulin Capsules

NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.

Compugen Announces Purchase Of Company Shares By Its Board Of Directors And Members Of Management

Compugen Announces Purchase Of Company Shares By Its Board Of Directors And Members Of Management

HOLON, Israel, March 26, 2019 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its entire board of directors and members of management purchased...

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in...

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Compugen Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen is Now Oversold (CGEN)

Compugen is Now Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Compugen (CGEN)

Oversold Conditions For Compugen (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Enters Oversold Territory (CGEN)

Compugen Enters Oversold Territory (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

When you get an unexpected rally, just go with it, Cramer says.

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Compugen

Relative Strength Alert For Compugen

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, announced today that it has achieved the third preclinical milestone pursuant to its cancer immunotherapy collaboration with Bayer HealthCare...

Stocks to Watch for 2016 M&A Deals

Stocks to Watch for 2016 M&A Deals

Look for 2015's record run of mergers and acquisitions to continue.

Compugen To Present At The Oppenheimer Healthcare Conference In New York

Compugen To Present At The Oppenheimer Healthcare Conference In New York

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial Officer of Compugen, will present a corporate overview and update at the Oppenheimer 26th Annual...

Compugen To Present At Jefferies 2015 Global Healthcare Conference In London

Compugen To Present At Jefferies 2015 Global Healthcare Conference In London

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Dr.

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the third quarter ending September 30, 2015.

Compugen Third Quarter 2015 Conference Call Scheduled For Tuesday, November 3, 2015 At 10:00 AM ET

Compugen Third Quarter 2015 Conference Call Scheduled For Tuesday, November 3, 2015 At 10:00 AM ET

Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, November 3, 2015 to review third quarter 2015 results.